Pharmesis International Ltd. (P31) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Pharmesis International Ltd. (Pharmesis) is a pharmaceutical company. The company carries out the research, development production, and commercialization of Western medicine and traditional Chinese Medicine. It provides formulated products such as anetholtrithione (ATT) for the treatment of illnesses relating to the liver and gall bladder. The company provides products such as kinna, longlife and health supplements. Pharmesis products are sold to approximately 2,000 hospitals all over the China. Its production facilities have 41,206 sq m, area and are located in the cities of Chengdu and Guilin in the Sichuan Province. The company’s research and development team collaborates with research institutes in China to identify and develop new pharmaceutical products. Pharmesis is headquartered in Chengdu, Sichuan, China.
Pharmesis International Ltd. Key Recent Developments
May 13, 2013: Pharmesis Reports Revenue Of RMB15.2m In Q1 2013
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table Of Contents
Pharmesis International Ltd. (P31) - Financial and Strategic SWOT Analysis Review Table of Contents
Section 1 - About the Company 6 Pharmesis International Ltd. - Key Facts 6 Pharmesis International Ltd. - Key Employees 7 Pharmesis International Ltd. - Key Employee Biographies 8 Pharmesis International Ltd. - Key Operational Employees 9 Pharmesis International Ltd. - Major Products and Services 10 Pharmesis International Ltd. - History 11 Pharmesis International Ltd. - Company Statement 12 Pharmesis International Ltd. - Locations And Subsidiaries 13 Head Office 13 Other Locations and Subsidiaries 13 Section 2 - Company Analysis 14 Pharmesis International Ltd. - Business Description 14 Pharmesis International Ltd. - SWOT Analysis 15 SWOT Analysis - Overview 15 Pharmesis International Ltd. - Strengths 15 Strength - Broad Product Offerings 15 Strength - Focused RandD Activities 15 Strength - Improved Financial Performance 15 Pharmesis International Ltd. - Weaknesses 16 Weakness - Geographical Concentration: China 16 Pharmesis International Ltd. - Opportunities 16 Opportunity - Growing Aged Population in China 16 Opportunity - Market Potential: HCV 16 Opportunity - Chinese Pharmaceutical Market 16 Pharmesis International Ltd. - Threats 16 Threat - Intense Competition 16 Threat - Stringent Government Regulations 17 Threat - Uncertain RandD Outcomes 17 Pharmesis International Ltd. - Key Competitors 18 Section 3 - Company Financial Ratios 19 Financial Ratios - Capital Market Ratios 19 Financial Ratios - Annual Ratios 20 Performance Chart 21 Financial Performance 21 Financial Ratios - Interim Ratios 22 Financial Ratios - Ratio Charts 23 Section 4 - Company's Recent Developments 24 May 13, 2013: Pharmesis Reports Revenue Of RMB15.2m In Q1 2013 24 Section 5 - Appendix 25 Methodology 25 Ratio Definitions 25 About GlobalData 29 Contact Us 29 Disclaimer 29
List of Tables
Pharmesis International Ltd., Key Facts 6 Pharmesis International Ltd., Key Employees 7 Pharmesis International Ltd., Key Employee Biographies 8 Pharmesis International Ltd., Key Operational Employees 9 Pharmesis International Ltd., Major Products and Services 10 Pharmesis International Ltd., History 11 Pharmesis International Ltd., Other Locations 13 Pharmesis International Ltd., Subsidiaries 13 Pharmesis International Ltd., Key Competitors 18 Pharmesis International Ltd., Ratios based on current share price 19 Pharmesis International Ltd., Annual Ratios 20 Pharmesis International Ltd., Interim Ratios 22 Currency Codes 25 Capital Market Ratios 25 Equity Ratios 26 Profitability Ratios 26 Cost Ratios 27 Liquidity Ratios 27 Leverage Ratios 28 Efficiency Ratios 28
List of Figures
Pharmesis International Ltd., Performance Chart (2009 - 2013) 21 Pharmesis International Ltd., Ratio Charts 23